- Inactivated Virus,
- Protein Subunit,
- Non-replicating Viral Vector,
- Repurposed Vaccines,
- RNA Vaccine,
- DNA Vaccine,
- Genetic Vaccine
COVID-19 vaccine market size is valued at USD billion in 2021 and is expected to reach a value of USD billion by 2028, expected to grow at a significant CAGR from 2022 to 2028. The global market provides a detailed overview and which can be segmented by vaccine type and technology. The COVID-19 vaccine market has been segmented by vaccine type into Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, and Genetic Vaccine. The RNA Vaccine segment is likely the largest and fastest-growing in terms of vaccine types. Based on technology, the COVID-19 vaccine is segmented into Vector-based, Nucleic acid-based, Protein-based, and Whole Viruses. According to precision business insights, the Vector-based segment is predicted to register the fastest growth rate during the forecast period.
Covid 19 Vaccine Market Key Development:
- In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.
- In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.
Covid 19 Vaccine Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
x%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
COVID-19 Vaccine Market Dynamics
With greater healthcare awareness, the focus on immunization has shifted significantly, and various government agencies are working to achieve this goal. For example, Immunise Australia is an Australian government program that helps people buy immunizations.
Asia-Pacific Got Significant Share
COVID-19 Vaccine Market
The Asia Pacific market is expected to witness the largest market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The COVID-19 vaccine market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Covid 19 Vaccine Market Segmentation
Vaccine Type
By Technology
- Vector-based,
- Nucleic acid-based,
- Protein-based,
- Whole Virus
By Geography
- North America,
- Europe,
- Asia Pacific,
- Latin America, and
- Middle East and Africa
Frequently Asked Questions
The COVID-19 vaccine market is projected to expand at a CAGR of x% during the forecast period.
The major global COVID-19 vaccine market players are ??? AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, Pfizer, Johnson & Johnson, BioNTech, CureVac, Serum Institute of India, Novavax, Sinovac, and Sinopharm.
Asia Pacific is the fastest-growing region for COVID-19 vaccine arket
| 1. Executive Summary |
| 2. Global COVID-19 Vaccine Market Introduction |
| 2.1. Global COVID-19 Vaccine Market Taxonomy |
| 2.2. Global COVID-19 Vaccine Market Definitions |
| 2.2.1. By Vaccine Type |
| 2.2.2. By Technology |
| 2.2.3. By Region |
| 3. Global COVID-19 Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global COVID-19 Vaccine Market Dynamic Factors - Impact Analysis |
| 3.6. Global COVID-19 Vaccine Market Competition Landscape |
| 4. Global COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global COVID-19 Vaccine Market, By Vaccine Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Inactivated Virus |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Protein Subunit |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Non-replicating Viral Vector |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Repurposed Vaccines |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. RNA Vaccine |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. DNA Vaccine |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Genetic Vaccine |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. Global COVID-19 Vaccine Market, By Technology, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Vector-based |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Nucleic acid-based |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Protein-based |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Whole Virus |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global COVID-19 Vaccine Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Region, 2024 - 2030 |
| 8. North America COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Inactivated Virus |
| 8.1.2. Protein Subunit |
| 8.1.3. Non-replicating Viral Vector |
| 8.1.4. Repurposed Vaccines |
| 8.1.5. RNA Vaccine |
| 8.1.6. DNA Vaccine |
| 8.1.7. Genetic Vaccine |
| 8.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Vector-based |
| 8.2.2. Nucleic acid-based |
| 8.2.3. Protein-based |
| 8.2.4. Whole Virus |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2024 - 2030 |
| 8.5. North America COVID-19 Vaccine Market Dynamics Trends |
| 9. Europe COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Inactivated Virus |
| 9.1.2. Protein Subunit |
| 9.1.3. Non-replicating Viral Vector |
| 9.1.4. Repurposed Vaccines |
| 9.1.5. RNA Vaccine |
| 9.1.6. DNA Vaccine |
| 9.1.7. Genetic Vaccine |
| 9.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Vector-based |
| 9.2.2. Nucleic acid-based |
| 9.2.3. Protein-based |
| 9.2.4. Whole Virus |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Rest of Europe |
| 9.4. Europe COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2024 - 2030 |
| 9.5. Europe COVID-19 Vaccine Market Dynamics Trends |
| 10. Asia-Pacific COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Inactivated Virus |
| 10.1.2. Protein Subunit |
| 10.1.3. Non-replicating Viral Vector |
| 10.1.4. Repurposed Vaccines |
| 10.1.5. RNA Vaccine |
| 10.1.6. DNA Vaccine |
| 10.1.7. Genetic Vaccine |
| 10.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Vector-based |
| 10.2.2. Nucleic acid-based |
| 10.2.3. Protein-based |
| 10.2.4. Whole Virus |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2024 - 2030 |
| 10.5. Asia-Pacific COVID-19 Vaccine Market Dynamics Trends |
| 11. Latin America COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Inactivated Virus |
| 11.1.2. Protein Subunit |
| 11.1.3. Non-replicating Viral Vector |
| 11.1.4. Repurposed Vaccines |
| 11.1.5. RNA Vaccine |
| 11.1.6. DNA Vaccine |
| 11.1.7. Genetic Vaccine |
| 11.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Vector-based |
| 11.2.2. Nucleic acid-based |
| 11.2.3. Protein-based |
| 11.2.4. Whole Virus |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2024 - 2030 |
| 11.5. Latin America COVID-19 Vaccine Market Dynamics Trends |
| 12. Middle East and Africa COVID-19 Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Inactivated Virus |
| 12.1.2. Protein Subunit |
| 12.1.3. Non-replicating Viral Vector |
| 12.1.4. Repurposed Vaccines |
| 12.1.5. RNA Vaccine |
| 12.1.6. DNA Vaccine |
| 12.1.7. Genetic Vaccine |
| 12.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Vector-based |
| 12.2.2. Nucleic acid-based |
| 12.2.3. Protein-based |
| 12.2.4. Whole Virus |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA COVID-19 Vaccine Market - Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2024 - 2030 |
| 12.5. MEA COVID-19 Vaccine Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Vaccine Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. AstraZeneca |
| 13.2.2. GlaxoSmithKline |
| 13.2.3. Moderna |
| 13.2.4. Gamaleya |
| 13.2.5. Bharat Biotech |
| 13.2.6. Pfizer |
| 13.2.7. Johnson & Johnson |
| 13.2.8. BioNTech |
| 13.2.9. CureVac |
| 13.2.10. Serum Institute of India |
| 13.2.11. Novavax |
| 13.2.12. Sinovac |
| 13.2.13. Sinopharm |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- AstraZeneca
- GlaxoSmithKline
- Moderna
- Gamaleya
- Bharat Biotech
- Pfizer
- Johnson & Johnson
- BioNTech
- CureVac
- Serum Institute of India
- Novavax
- Sinovac
- Sinopharm